Neonatal seizures
**Flow Chart: Assessment and management**

**Baby with suspected seizure activity**

**Observe and monitor:**
- Seizure activity
- Temperature, heart rate, respiratory rate & effort, BP, O₂ saturation

*Treat cardiorespiratory compromise*

**Assessment:**
- Review history (maternal, perinatal, family)
- Physical examination
- Neurological examination
- Investigate for underlying cause as required
  - Refer to flowchart: *Investigations*

**Management:**
- Treat underlying cause
  - Refer to other QCG guidelines
- Commence AEDs if seizures:
  - Duration > 3 minutes
  - More than 2 brief episodes
  - Detected on EEG
- Initiate ongoing communication with parent(s)
- Obtain advice from neonatologist as required

**Seizure activity**

**Can underlying cause be treated with immediate effect?**

- Yes
- Treat underlying cause(s) as indicated:
  - Hypoglycaemia—Refer to QCG Newborn hypoglycaemia
  - Infection—Refer to QCG EOGBSD
  - HIE—Refer to QCG HIE

- No

**Loading dose:**
- phenobarbital 20 mg/kg IV

**Seizure activity ceased?**

- Yes

**Treatment:**
- If seizures intractable within hours of birth & resistant to AEDs consider pyridoxine 50–100 mg IV
- Additional doses of phenobarbital:
  - 5–10 mg/kg IV (to total dose of 40 mg/kg)
- Second line drug:
  - Phenytoin 15-20 mg/kg IV
  - Midazolam 0.15 mg/kg IV
  - Levetiracetam 10 mg/kg IV twice per day
  - Topiramate 5 mg/kg orally
  - Clonazepam
    - 100 micrograms/kg IV
  - Lignocaine 2 mg/kg IV and follow with IV infusion

- No

**Maintenance therapy:**
- For difficult to control or prolonged seizures or abnormal EEG

**Consider ceasing AEDs if:**
- Seizures controlled and neurological examination normal OR
- Neurological examination abnormal but EEG normal

**Abbreviations:**
- AED: Anti-epileptic drug(s); BP: Blood pressure; EEG: Electroencephalogram; EOGBSD: Early onset Group B Streptococcal disease; HIE: Hypoxic ischaemic encephalopathy; IV: Intravenous; QCG: Queensland Clinical Guidelines, >: Greater than
Flow Chart: Investigations

Acute symptomatic seizure

Initial screen

Pathology

Blood
- BGL
- Urea and electrolytes Ca, Mg, Na
- FBC
- Blood culture

CSF
- Microscopy and bacterial culture
- Glucose
- Protein

Urine
- Culture

Imaging
- Cranial USS and/or MRI

Initial screen positive?

No

Yes

Subsequent investigations

Guided by specific clinical features of baby or expert advice

Pathology

Blood
- Lactate
- Ammonia/LFTs
- Metabolic screen
  - Acylcarnitines
  - Biotinidase
  - Copper, caeruloplasmin and hair analysis
- Plasma amino acids
- Congenital infection screen
  - Toxoplasma
  - Rubella
  - CMV
  - HSV
  - Syphilis
  - Enterovirus
  - Varicella zoster
  - Parovirus B19

CSF
- CSF amino acids
- Paired CSF and plasma glucose and lactate
- Neurotransmitters
- HSV, enterovirus
- Lactate, pyruvate and amino acids

Urine
- Amino acids
- Organic acids
- Alpha aminoadipic semialdehyde
- CMV

Consider genetic tests

Neurophysiology
- Commence continuous EEG monitoring if available
- Record EEG if available

Treat underlying cause(s) as indicated

- Hypoglycaemia—Refer to QCG
- Newborn hypoglycaemia
- Infection—Refer to QCG EOGBS
- HIE—Refer to QCG HIE
- Other

Subsequent investigations as indicated

Abbreviations: BGL Blood glucose level; CMV Cytomegalovirus; CSF Cerebrospinal fluid; EEG Electroencephalogram; EOGBS Early onset Group B streptococcal disease; FBC Full blood count; HIE Hypoxic ischaemic encephalopathy; HSV Herpes simplex virus; LFTs Liver function tests; MRI Magnetic resonance imaging; QCG Queensland Clinical Guidelines; USS Ultrasound scan
### Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>AED</td>
<td>Antiepileptic drugs</td>
</tr>
<tr>
<td>aEEG</td>
<td>Amplitude integrated electroencephalogram</td>
</tr>
<tr>
<td>BGL</td>
<td>Blood glucose level</td>
</tr>
<tr>
<td>BP</td>
<td>Blood pressure</td>
</tr>
<tr>
<td>cEEG</td>
<td>Continuous electroencephalogram</td>
</tr>
<tr>
<td>CMV</td>
<td>Cytomegalovirus</td>
</tr>
<tr>
<td>CNS</td>
<td>Central nervous system</td>
</tr>
<tr>
<td>CSF</td>
<td>Cerebro-spinal fluid</td>
</tr>
<tr>
<td>EEG</td>
<td>Electroencephalogram</td>
</tr>
<tr>
<td>GMA</td>
<td>General movements assessment</td>
</tr>
<tr>
<td>HIE</td>
<td>Hypoxic-ischaemic encephalopathy</td>
</tr>
<tr>
<td>HSV</td>
<td>Herpes simplex virus</td>
</tr>
<tr>
<td>IM</td>
<td>Intramuscular</td>
</tr>
<tr>
<td>IV</td>
<td>Intravenous</td>
</tr>
<tr>
<td>IVH</td>
<td>Intraventricular haemorrhage</td>
</tr>
<tr>
<td>MRI</td>
<td>Magnetic resonance imaging</td>
</tr>
<tr>
<td>PCR</td>
<td>Polymerase chain reaction</td>
</tr>
<tr>
<td>USS</td>
<td>Ultrasound scan</td>
</tr>
<tr>
<td>VLBW</td>
<td>Very low birth weight</td>
</tr>
</tbody>
</table>

### Definitions

<table>
<thead>
<tr>
<th>Term</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Apoptosis</td>
<td>Cell death¹</td>
</tr>
<tr>
<td>Automatisms</td>
<td>Non-purposeful, stereotyped, and repetitive behaviours most common are oral lip smacking, chewing, swallowing and cycling²,³; performed without conscious control¹</td>
</tr>
<tr>
<td>Hydrocephalus ex-vacuo</td>
<td>Increased cerebro spinal fluid (CSF) volume but normal pressure when there is shrinkage of brain substance following damage to the brain caused by stroke or injury⁴</td>
</tr>
<tr>
<td>Hyperekplexia</td>
<td>Neurologic disorder where there is a pronounced startle response to tactile or acoustic stimuli, and hypertonia⁵</td>
</tr>
<tr>
<td>Hypsarrhythmia</td>
<td>Abnormal inter-ictal pattern with electroencephalogram (EEG) high amplitude and irregular waves and spikes with background of chaotic and disorganised activity⁶</td>
</tr>
<tr>
<td>Ictal</td>
<td>Relating to seizures¹</td>
</tr>
<tr>
<td>Lissencephaly</td>
<td>Rare, gene-linked brain malformation where there is absence of normal convolutions (folds) in the cerebral cortex and an abnormal, small head (although normal size at birth)¹</td>
</tr>
<tr>
<td>Opisthotonos</td>
<td>Abnormal extensor posture where the head and lower limbs are bent backwards and the body is arched forward¹</td>
</tr>
<tr>
<td>Polymicrogyria</td>
<td>Abnormal development of the brain before birth characterised by too many folds (gyri) that are unusually small⁵</td>
</tr>
<tr>
<td>Schizencephaly</td>
<td>A rare congenital anomaly where unilateral or bilateral clefts in the cerebral hemispheres develop that may be filled with cerebrospinal fluid⁵</td>
</tr>
<tr>
<td>Spasticity</td>
<td>Muscular hypertonicity with increased resistance to stretch⁷</td>
</tr>
</tbody>
</table>
Table of Contents

1 Introduction ................................................................................................................. 7
1.1 Incidence .................................................................................................................. 7
1.2 Consultation and referral ......................................................................................... 8
2 Aetiology ..................................................................................................................... 9
2.1 CNS causes ............................................................................................................ 9
2.2 Other causes .......................................................................................................... 10
2.3 Presentation .......................................................................................................... 11
3 Seizure description ................................................................................................... 11
3.1 Classification ........................................................................................................ 11
3.2 Clinical presentation ............................................................................................. 12
3.3 Non seizure activity in babies .............................................................................. 13
3.3.1 Jitteriness versus seizures .............................................................................. 13
4 Diagnosis ................................................................................................................. 14
4.1 Assessment of baby ............................................................................................. 14
4.2 Investigations ........................................................................................................ 15
4.3 Subsequent investigations ................................................................................... 16
5 Management and treatment ..................................................................................... 17
5.1 Observation and monitoring ................................................................................ 17
5.1.1 Continuing care ............................................................................................ 18
6 Drug therapy ............................................................................................................ 19
6.1 Anti-epileptic drugs .............................................................................................. 20
6.1.1 Phenobarbital ................................................................................................. 20
6.1.2 Phenytoin ....................................................................................................... 21
6.1.3 Midazolam ...................................................................................................... 21
6.1.4 Levetiracetam ................................................................................................. 22
6.1.5 Topiramate ..................................................................................................... 22
6.1.6 Clonazepam ................................................................................................... 23
6.1.7 Lidocaine (lignocaine) .................................................................................. 23
6.2 Pyridoxine (vitamin B6) deficiency ...................................................................... 24
7 Ongoing care ............................................................................................................. 25
7.1 Discharge planning ............................................................................................... 25
7.2 Prognosis .............................................................................................................. 25
7.3 Outcomes .............................................................................................................. 26
7.4 Follow up ............................................................................................................. 27
References ................................................................................................................... 28
Appendix A Abnormal movements ............................................................................. 31
Acknowledgements ..................................................................................................... 32

List of Tables
Table 1. Consultation, retrieval or transfer ................................................................. 8
Table 2. CNS causes .................................................................................................. 9
Table 3. Other causes ............................................................................................... 10
Table 4. Presentation ................................................................................................. 11
Table 5. Seizure type ................................................................................................ 12
Table 6. Non-seizure activity .................................................................................... 13
Table 7. Jitteriness versus seizures ......................................................................... 13
Table 8. Assessment ................................................................................................. 14
Table 9. Initial investigations ................................................................................... 15
Table 10. Subsequent investigations ....................................................................... 16
Table 11. Initial assessment and management ....................................................... 17
Table 12. Continuing care ....................................................................................... 18
Table 13. Principles .................................................................................................. 19
Table 14. Phenobarbital ............................................................................................ 20
Table 15. Phenytoin ................................................................................................. 21
Table 16. Midazolam ............................................................................................... 21
Table 17. Levetiracetam ........................................................................................... 22
Table 18. Topiramate ............................................................................................... 22
Table 19. Clonazepam ............................................................................................. 23
Table 20. Lidocaine (lignocaine) ............................................................................ 23
Table 21. Pyridoxine ............................................................................................... 24
Table 22. Prognosis and outcome ........................................................................... 25
Table 23. Outcomes ................................................................................................. 26
Table 24. Follow up ................................................................................................. 27
1 Introduction

Neonatal seizures are a neurological emergency\(^6\) that are difficult to diagnose and treat.\(^7,8\) The clinical presentation of neonatal seizures is variable and clinical features of a seizure are often absent or non-specific.\(^6,7\) This has led to under-diagnosis and occasional over-diagnosis \(^7\) of neonatal seizures. Newborn babies can have movements that can be mistaken for seizures, where the electroencephalogram (EEG) is normal.\(^7\)

The majority of seizures demonstrated on video EEG monitoring do not have overt clinical signs.\(^6\) Neonatal seizures encompass events that have a proven underlying epileptic mechanism detected by an EEG.\(^6\) They most commonly occur due to neonatal encephalopathy often due to brain hypoxic ischemia.\(^9\) Subclinical seizures may manifest as apnoea in the term baby however when it is the sole sign of a seizure it is not usually accompanied by bradycardia.\(^10,11\)

Seizures are a sign of neurological dysfunction and neonates\(^12\) are at especially high risk of seizures compared to other age groups.\(^13\) They reflect different pre-, peri-, or postnatal disorders of the central nervous system (CNS).\(^8\) The reasons are multifactorial and include the relative excitability of the developing neonatal brain as well as the high risk for brain injury due to hypoxia, ischaemia, stroke, intracranial haemorrhage and metabolic disturbance.\(^13\)

Seizures can be associated with greater risk of long term neurodevelopmental disabilities.\(^8\) Both clinical and electrographic seizures are associated with neurological sequelae including motor and cognitive deficits, an increased risk of epilepsy in later life and hypoxic induced brain injury as seen in hypoxic-ischaemic encephalopathy (HIE).\(^13\)

1.1 Incidence

Seizures occur more frequently in the neonatal period than at any other time.\(^14,15\) Preterm babies, especially those at lower gestational age and birth weights, have a higher incidence of neonatal seizures due to the associated morbidity of cerebral insults such as intraventricular haemorrhage and periventricular leucomalacia.\(^16,17\)

Generally:

- Term babies: 1.5–5/1000 live births\(^8,10,18,19\)
- Birth weight:
  - 1500–2500: 4.4/1000 live births
  - Less than 1500 grams: 55–130/1000 live births
  - Less than 1000 grams: up to 64/1000 live births\(^20\)
- Babies with HIE: 37%–57\(^\%\)\(^15\)
### 1.2 Consultation and referral
Clinical management is provided within the capability of the service to ensure the baby’s clinical and safety needs are met.21

Table 1. Consultation, retrieval or transfer

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Consideration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Level 1–5</td>
<td>• Provide care according to Clinical Service Capability Framework21</td>
</tr>
</tbody>
</table>
| Level 1        | • Provide basic life support for baby  
• Contact local retrieval services for:  
  o Advice and to discuss initial management with neonatologist  
  o Retrieval to higher level service                                                |
| Level 2 or 3   | • Contact local retrieval services for:  
  o Advice and to discuss initial management with neonatologist  
  • Arrange transfer or retrieval (dependent on baby’s condition) including:  
    o BGL less than 1.5 mmol/L  
    o Known neonatal abstinence syndrome (NAS)  
    o Requires cardio-respiratory support  
    o Abnormal physical or neurological examination  
    o Seizures intractable within hours of birth and resistant to first line anti-epileptic drugs (AEDs)  
    o Further investigations required including pathology, neuroimaging or neurophysiology  
  • Correct abnormal blood glucose level (BGL)  
  • Assess, manage and monitor airway, breathing and circulation  
  • Initiate and document discussion with parents                                                                 |
| Level 4        | • Contact local retrieval services:  
  o For advice and to discuss management with neonatologist:  
  o If ongoing investigations not available at facility including magnetic resonance imaging and EEG  
  o If birthweight is less than 1500 g or gestation less than 32 weeks |
| Level 5        | • Contact local retrieval services for baby if birthweight is less than 1000 g or gestation less than 29 weeks                                        |
| Retrieval or transfer | • Contact local retrieval services for retrieval or transfer to higher level service                                                                      |
2 Aetiology

Seizures occur when excessive and synchronised depolarisation occurs in a large group of neurons. Most neonatal seizures occur in the context of a diagnosable underlying condition. These conditions include poor cerebral perfusion (including HIE), haemorrhage, hypoglycaemia, head trauma, electrolyte imbalance or stroke (meningitis or encephalitis).

2.1 CNS causes

Table 2. CNS causes

<table>
<thead>
<tr>
<th>Cause</th>
<th>Comment</th>
</tr>
</thead>
</table>
| Hypoxic-ischaemic encephalopathy | - Seen in preterm and term babies though clinical features may differ with gestation
|                              | - Usually present within first 72 hours of life, typically between four and 24 hours after birth
|                              | - May be subtle, clonic or myoclonic seizures                          |
|                              | - Results from excessive depolarisation caused by a disruption to the adenosine triphosphate (ATP)-dependent pump |
|                              | - Refer to Queensland Clinical Guideline Hypoxic-ischaemic encephalopathy |
| Intracranial haemorrhage     | - Generally more common in preterm than term babies
|                              | - Subdural haemorrhage usually associated with cerebral contusion and more common in term babies
|                              | - Intraventricular haemorrhage (more common in preterm babies)
|                              | - Parenchymal haemorrhage
|                              | - Subarachnoid haemorrhage (more common in term babies)
|                              | - Subgaleal haemorrhage
|                              | - Germinal matrix intraventricular haemorrhage (IVH) (more common in preterm babies especially born before 34 weeks gestation)—subtle seizures often present |
| Infection of CNS             | - Acute infection requires urgent investigation and consideration of treatment pending results |
|                              | - Important causes requiring urgent investigation:                     |
|                              |   - Bacterial meningitis (consider Escherichia coli and Streptococcus agalactiae) (Group B Streptococcus) and Listeria monocytogenes
|                              |   - Septicaemia without meningitis may also result in seizures          |
|                              | - Encephalitis—causes include:                                           |
|                              |   - Viruses including Herpes simplex (HSV), Enterovirus, or Cytomegalovirus (CMV)
|                              |   - Parasites such as Toxoplasma gondii or                              |
|                              |   - Bacterial pathogens such as Escherichia coli and Streptococcus pneumoniae |
|                              | - Congenital infections may also require urgent investigation and treatment if suspected active infection |
| Other cerebrovascular        | - Arterial stroke                                                        |
|                              | - Venous stroke                                                          |

Refer to online version, destroy printed copies after use
## 2.2 Other causes

Table 3. Other causes

<table>
<thead>
<tr>
<th>Cause</th>
<th>Comment</th>
</tr>
</thead>
</table>
| **Biochemical**              | • Hypoglycaemia  
• Hypocalcaemia  
• Hypomagnesaemia\(^8,13,22\)  
• Hyponatraemia\(^8,13\)  
• Hypernatraemia\(^8\)  
• Urea cycle disturbances resulting in ammonia accumulation\(^10\) |
| **Inborn errors of metabolism** | • Multifocal and generalised myoclonic jerks often intermixed with tonic signs, abnormal eye movement, grimacing or irritability  
• Time of onset:  
  o Depends on the disorder:  
    ▪ Disorder resulting in key metabolite deficiency can present very early (e.g. pyridoxine dependent seizures)  
    ▪ Disorders resulting accumulation of a toxic product may present late  
  o May also vary with severity and timing (e.g. hypoxia, infection)  
• Usually seen after baby starts feeding\(^22\)  
• Rare inborn errors of metabolism including pyridoxine responsive seizures\(^8,10,30\) and other vitamin dependency  
• Baby may be in poor condition at birth  
• Seizure activity may be accompanied by:  
  o Metabolic acidosis, electrolyte disturbance, abdominal distension, feed intolerance  
  o Misdiagnosis if HIE or sepsis are incorrectly diagnosed\(^30\)  
• May have maternal report of abnormal intrauterine movements (fluttering or hiccoughs)\(^30,31\) |
| **Other**                    | • Drug withdrawal syndromes\(^8,10\)  
  o Refer to Queensland Clinical Guidelines *Perinatal substance use—neonatal*\(^32\) and *Perinatal substance use—maternal*\(^33\)  
• Benign familial neonatal seizures  
  o Result from gene mutation  
  o Remit within first few months and are associated with good neurological outcomes\(^8\)  
• Benign neonatal seizure syndromes  
  o Typically present on day five  
  o Often multifocal  
  o CSF usually unremarkable\(^8,22\)  
• A range of genetic disorders causing epilepsy syndromes e.g. early onset epileptic encephalopathy; Ohtahara syndrome |
| **Developmental/congenital** | • Abnormality of brain development\(^8\) |
2.3 Presentation

Neonatal seizures evolve over time. The peak incidence occurs between 12 and 24 hours of age but the time of onset is dependent on aetiology and treatment. Often the seizures cease by 72 hours of age. The typical time of presentation is identified in Table 4. Presentation, but the day of onset may be variable.

Table 4. Presentation

<table>
<thead>
<tr>
<th>Typical onset</th>
<th>Cause</th>
</tr>
</thead>
</table>
| Day 1<sup>11,34</sup> | Traumatic brain injury:  
  o Haemorrhage—subarachnoid, intraventricular, intracerebral  
  o Subdural haematoma  
  o Sub-galeal  
  Hypoxic ischaemic insult  
  Stroke (arterial)  
  Infection:  
  o Viral or bacterial  
  Hypoglycaemia  
  o Preterm baby  
  o Small for gestational age  
  o Maternal gestational diabetes  
  o Polycythaemia  
  Severe neurometabolic disorders:  
  o Sulphite oxidase deficiency  
  o Non-ketotic hyperglycaemia  
  o Urea cycle defects  
  Drug withdrawal syndromes  
  Pyridoxine dependent  |
| Day 2<sup>11,34</sup> | Stroke (venous thrombosis)  
  Glucose transporter deficiency  
  Electrolyte deficiency/disturbance:  
  o Hyponatremia  
  o Hypometraemia  
  o Hypocalcaemia  
  o Hypomagnesaemia  
  Infection  |
| Day 3<sup>11,34</sup> | Neurometabolic disorders  
  Cerebral malformations:  
  o Lissencephaly  
  o Polymicrogyria  
  o Schizencephaly  
  Other genetic abnormalities  
  Infection  |

3 Seizure description

Clinically a seizure is a paroxysmal alteration in neurological function of behavioural, motor or neurological function. Underlying the clinical manifestation is an electrographic seizure.

3.1 Classification

Neonatal seizures are either clinical or electrographical (if an EEG is in place and shows a seizure pattern). Clinical seizures can be classified as:<sup>2,35</sup>

- Clonic–recurrent muscle contraction
- Tonic–sustained muscle contraction
- Myoclonic–brief active muscle contraction
- Subtle–automatisms, autonomic phenomena, ocular phenomena and include seizures with apnoea
- Focal–involving one part of the brain and affecting one side of the body<sup>11</sup>
  - Multifocal–involving more than one part of the brain affecting several body parts, asynchronous and migratory<sup>11</sup>
- Generalised–involving bilateral brain structures, synchronous and non-migratory<sup>11</sup>
### 3.2 Clinical presentation

Table 5. Seizure type

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Comment</th>
</tr>
</thead>
</table>
| **Clonic**<sup>3,10,22,36</sup> | - Rhythmic movements—usually slow at a rate of one to three per second  
  - May involve face, arms, legs, or trunk  
  - May be focal (one part or side of body) or multifocal (multiple areas of the body shifting from one site to the other)  
  - Can be identified by clinical observation  
  - Focal clonic have best outcomes<sup>36</sup>  
  - Primarily found in term babies<sup>37</sup> |
| **Tonic** | - Generalised tonic seizures—sustained symmetric posturing of limbs, trunk, and neck  
  - More common in preterm babies<sup>20,35</sup> who have poorer prognosis<sup>20</sup>  
  - May be flexor, extensor, or mixed extensor/flexor<sup>3</sup>  
  - Involve both upper and lower extremities:  
    - Tonic extension (resemble decerebrate posturing) or  
    - Tonic flexion of arms and extension of legs (mimics decorticate posturing)<sup>10,36</sup>  
    - May involve one extremity or whole body axial musculature in a opisthotonic fashion<sup>22</sup>  
  - May be provoked or intensified by stimulation  
  - May be suppressed by restraint or repositioning  
  - Presumed pathophysiology is non-epileptic<sup>3</sup>  
  - Focal tonic seizures of one extremity:  
    - Especially associated with eye deviation<sup>7</sup>  
    - Cannot be provoked by stimulation or suppressed by restraint<sup>3</sup> |
| **Myoclonic** | - Repeated often non-rhythmic, brief shock like jerks<sup>7</sup>  
  - Random, single, rapid contractions of muscle groups of the limbs, face, or trunk  
  - Tendency to affect flexor muscle groups  
  - Caused by sudden contraction or relaxation of one or more muscles<sup>7</sup>  
  - Resemble clonic movements but are quicker and gives appearance of jerky baby  
  - Do not have rhythmic nature of clonic seizures<sup>7</sup>  
  - May occur in one extremity (i.e. focal) or in several body part (i.e. multifocal) or fragmentary<sup>3,10,22,36</sup>  
  - Typically not associated with electrographic correlates<sup>22,36</sup>  
  - Typically not repetitive or may recur at a slow rate  
  - Each one lasts approximately one microsecond or less<sup>7</sup>  
  - May be provoked by stimulation<sup>3</sup>  
  - Generalised myoclonic seizure more likely to have EEG changes<sup>7</sup>  
  - Include burst suppression, focal sharp waves and hypsarrhythmia<sup>36</sup>  
  - Occur rarely but carry worst prognosis<sup>35,36</sup> |
| **Subtle** | - More common in term babies<sup>36</sup> but also found with preterm babies<sup>35</sup>  
  - May have<sup>10,36</sup>:  
    - Ocular–tonic horizontal eye deviation or sustained eye opening with ocular fixation or cycle fluttering  
    - Oral-facial-lingual movements—chewing movements, tongue thrusting, lip smacking  
    - Limb movements—cycling, paddling, boxing jabs  
    - Autonomic CNS phenomena—tachycardia, bradycardia  
    - Apnoic spells:  
      - Area rare manifestation of seizures and usually without accompanying bradycardia (unless prolonged hypoxaemia)  
      - More commonly seen in term babies than preterm<sup>11</sup> |
3.3 Non seizure activity in babies

Table 6. Non-seizure activity

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Comment</th>
</tr>
</thead>
</table>
| Jitteriness             | • Recurrent tremor  
• Reducible by tactile stimuli, holding or flexing the affected body part  
• Does not affect the face  
• Not associated with eye deviation or autonomic change  
• Tremulousness of all limbs or just one limb  
• May also have a pathological basis  
• Commonly seen in many of the same conditions that are associated with neonatal seizures, e.g. drug withdrawal (from maternal drug ingestion), HIE, hypocalcaemia, and hypoglycaemia  
• Can clinically differentiate from seizures by disappearance with physical restraint (by holding the baby) and also a lack of associated features e.g. tachycardia or apnoea  |
| Excessive startles      | • Markedly excessive startles relative to the stimulation, e.g. auditory, touch and tonic stiffening  
• Can be a sign of an encephalopathy  
• Can also be seen in hyperekplexia  
• Can be stopped by flexion of the forehead to the chest  |
| Benign neonatal sleep myoclonus | • Benign condition in which the infant has myoclonic jerks during sleep  
• Involves one or more limbs—more commonly observed in arms  
• Limb movements in slow wave sleep often just after falling asleep or waking up  
• Can be quite dramatic—whole body may shake  
  o Ceases immediately when the baby awakens  
• Can occur in rapid succession  
• May worsen if baby is held  |
| Tremor                  | • Involuntary generalised movement  
• Rhythmical oscillating around a fixed axis  |
| Clonus                  | • Sustained and rhythmical  
• Upper motor neuron lesion  
• Involuntary muscle contractions and relaxation in muscle around a joint  
• Can be stopped by change of position of joint  
• Can be provoked by quick movements of joint, e.g. ankle dorsiflexion  |

3.3.1 Jitteriness versus seizures

Table 7. Jitteriness versus seizures

<table>
<thead>
<tr>
<th>Clinical feature</th>
<th>Jitteriness</th>
<th>Seizure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abnormal gaze or eye movement</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>Predominant movement</td>
<td>Tremor, rapid, oscillatory</td>
<td>Clonic, jerking, tonic</td>
</tr>
<tr>
<td>Movements cease with passive flexion</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Stimulus provoked movements</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Conscious state/ autonomic change</td>
<td>Awake or asleep</td>
<td>Altered</td>
</tr>
</tbody>
</table>
4 Diagnosis

Seizures can be difficult to diagnose because abnormal movements in the newborn baby may either be seizure activity (with seizures shown on an EEG) or simply abnormal movements without electrographic seizure.10,19 However, electrographical seizures may not be associated with abnormal movements or other clinical correlate.19 Approximately one third of neonatal seizures display clinically correlate with simultaneous video EEG recordings.39 The differential diagnosis for neonatal seizures is broad and includes structural, metabolic and genetic causes.13

4.1 Assessment of baby

Table 8. Assessment

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical evaluation</td>
<td>• Less accurate than EEG</td>
</tr>
<tr>
<td></td>
<td>• Does not identify subclinical or non-convulsive seizures13</td>
</tr>
<tr>
<td>History10,13</td>
<td>• Maternal antenatal history including:</td>
</tr>
<tr>
<td></td>
<td>o Previous miscarriages</td>
</tr>
<tr>
<td></td>
<td>o Gestational diabetes (causing neonatal hypoglycaemia)</td>
</tr>
<tr>
<td></td>
<td>o Infections and any treatment received (including sexually transmitted disease) particularly HSV, Syphilis, CMV and Toxoplasmosis</td>
</tr>
<tr>
<td></td>
<td>o Travel history for risk of Zika virus29 that may cause congenital abnormalities including microcephaly28</td>
</tr>
<tr>
<td></td>
<td>o Use of prescription and illicit drugs</td>
</tr>
<tr>
<td></td>
<td>o Clotting or bleeding tendencies</td>
</tr>
<tr>
<td></td>
<td>o Pre-eclampsia</td>
</tr>
<tr>
<td></td>
<td>o Hiccoughing or fluttering in-utero as a clue to seizure activity usually when metabolic disorder is present30</td>
</tr>
<tr>
<td></td>
<td>• Family history of epilepsy especially maternal in infancy or other family members (consanguinity)</td>
</tr>
<tr>
<td></td>
<td>• Perinatal history including type of birth and resuscitation and any:</td>
</tr>
<tr>
<td></td>
<td>o Fetal distress</td>
</tr>
<tr>
<td></td>
<td>o Birth trauma</td>
</tr>
<tr>
<td></td>
<td>o Perinatal asphyxia</td>
</tr>
<tr>
<td>Examination10,13</td>
<td>• Physical examination:</td>
</tr>
<tr>
<td></td>
<td>o Congenital anomalies</td>
</tr>
<tr>
<td></td>
<td>o Head circumference as microcephaly may be indicative of underlying brain malformation</td>
</tr>
<tr>
<td></td>
<td>o Birthmarks</td>
</tr>
<tr>
<td></td>
<td>o Somatic abnormalities</td>
</tr>
<tr>
<td></td>
<td>o Facial dysmorphology</td>
</tr>
<tr>
<td></td>
<td>• Abnormal neurological examination</td>
</tr>
<tr>
<td></td>
<td>• Signs of sepsis[refer to Queensland Clinical Guideline Early onset Group B streptococcal disease]40</td>
</tr>
<tr>
<td>Observations</td>
<td>• Monitor and record vital signs including heart rate, respiratory rate and effort, oxygen saturations, temperature, colour, blood pressure as indicated (e.g. if phenytoin administered)</td>
</tr>
<tr>
<td></td>
<td>• Observe and record seizure activity:</td>
</tr>
<tr>
<td></td>
<td>o Date, time and duration of any event</td>
</tr>
<tr>
<td></td>
<td>o Whether seizures are stereotypical with clear onset and offset</td>
</tr>
<tr>
<td></td>
<td>o Type of seizure (subtle, tonic, clonic, myoclonic and if focal or generalised)</td>
</tr>
<tr>
<td></td>
<td>o Abnormal eye movements</td>
</tr>
<tr>
<td></td>
<td>o Progression of events</td>
</tr>
<tr>
<td></td>
<td>o Autonomic changes, e.g. apnoea, hypotension, hypertension</td>
</tr>
<tr>
<td></td>
<td>o Any provoking stimuli, e.g. handling, noise</td>
</tr>
<tr>
<td></td>
<td>o Whether activity can be stopped or modified with posture or restraint</td>
</tr>
<tr>
<td></td>
<td>o EEG correlate if concurrent monitoring in place</td>
</tr>
<tr>
<td></td>
<td>• Document response to medications administered</td>
</tr>
</tbody>
</table>
4.2 Investigations

Investigations are dependent on the individual baby and circumstances including the likely cause of the seizures. Consider the maternal history and the baby’s history including presentation and type of seizures and response to treatment. Investigations are stratified according to possible cause and initial investigations are undertaken when a baby presents with neonatal seizures.

Table 9. Initial investigations

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Comment/good practice point</th>
</tr>
</thead>
</table>
| Blood$^{10,30}$ | - BGL  
- Urea, electrolytes and calcium, magnesium and sodium  
- Full blood count  
- Blood cultures |
| CSF$^{13,41}$ | - Microscopy and bacterial culture  
- PCR (bacterial and viral)  
- Glucose  
- Protein  
- Blood  
- Colour |
| Urine$^{39}$ | - Microscopy and culture |
| Imaging$^{13,36}$ | - USS for detection of intra-ventricular and parenchymal haemorrhage$^{36}$  
- Magnetic resonance imaging:  
  - Preferable to computed tomography or (USS)  
  - Greater sensitivity in identifying brain malformations, intracranial haemorrhage and ischaemic damage$^{10}$  
  - Does not aid the diagnosis of seizures but can be useful for diagnosing intracranial lesions associated with seizures$^{42}$  
  - Use if the aetiology is not identified and seizures resistant to usual AEDs  
  - Diagnostic for cerebral dysgenesis, lissencephaly and other neuronal migration disorders$^{36}$  
  - Timing is dependent on suspected cause of seizures e.g. as soon as possible for suspected brain malformation or serious intracranial haemorrhage and day 4–8 for baby with HIE [Refer to Queensland Clinical Guideline Hypoxic-ischaemic encephalopathy (HIE)]$^{24}$ |
### 4.3 Subsequent investigations
Table 10. Subsequent investigations are guided by the baby’s clinical features or expert opinion.

Table 10. Subsequent investigations

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Comment</th>
</tr>
</thead>
</table>
| **Blood** \(^{10,30,43}\) | - Lactate  
- Ammonia  
- Liver function tests  
- Thrombophilia screen  
- Metabolic screen  
  - Acylcarnitines\(^{41}\)  
  - Biotinidase  
  - Copper, caeruloplasmin and hair analysis  
  - Amino acids |
| **CSF** \(^{10,11,43,44}\) | - Amino acids  
- Neurotransmitters  
- HSV, Enterovirus  
- Lactate, pyruvate and amino acids  
- Paired CSF and plasma glucose, lactate and pyruvate\(^{11,30}\) |
| **Urine** \(^{10,36}\) | - Organic acids\(^3\)  
- Metabolic screen including ketones, reducing substances, amino acids  
- Alpha aminoadipic semialdehyde  
- CMV\(^{35}\) |
| **Other** | - Congenital infection screen\(^{10,35,43}\)  
  - Toxoplasmosis  
  - Rubella  
  - CMV  
  - HSV  
  - Syphilis  
  - Enterovirus  
  - Varicella zoster  
  - Parovirus B19  
  - Consider genetic tests\(^{3,13,43}\) |
| **Neurophysiology** | - Commence continuous EEG monitoring if available\(^{12}\)  
- Record EEG if available\(^6\)  
- EEG:  
  - Has a diagnostic and prognostic role  
  - Only way to confirm clinical event is seizure activity\(^6,13,42\)  
    - A standard non-continuous EEG of 30 minutes may be performed when there is no seizure activity and result in a false negative result  
  - Conventional, prolonged, continuous video-EEG (cEEG):  
    - Gold standard for detecting neonatal seizures\(^6,13,42\)  
    - Recommended for babies at high risk for seizures and/or paroxysmal events\(^13\)  
  - Amplitude integrated EEG (aEEG):  
    - Convenient bedside tool with only four electrodes  
    - Lower sensitivity and specificity than cEEG  
    - Lower sensitivity for brief, focal seizures or distant from recording electrodes\(^13\)  
    - Useful also for monitoring background brain activity (e.g. identifying variability as a sign of neurological wellbeing)  
  - Identification of longer duration seizures and status epilepticus\(^6\) |
5 Management and treatment

The principles for acute symptomatic neonatal seizure management include:\(^8,^{13,35}\)
- Rapid and accurate identification of seizures clinically and where possible by EEG
  - EEG is usually not available during first clinical seizure
- Avoidance of misdiagnosis
- Titration of medication(s) to stop electrographic seizures
- Early discontinuation of medications once seizures have ceased
- Prevention of secondary problems by maintaining normal physiological temperature, blood glucose, oxygenation, ventilation and blood pressure

5.1 Observation and monitoring

Table 11. Initial assessment and management

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Comment/good practice point</th>
</tr>
</thead>
</table>
| Resuscitation | - Establish adequate airway, ventilation and perfusion\(^{13,35,39}\)  
  - Minimise additional postnatal hypoxaemia and hyper- or hypocapnia  
  - Commence cardio-respiratory, oxygen saturation and blood pressure monitoring in babies:  
    - At risk of encephalopathy including alterations in autonomic functioning (vital signs) which may be indicative of seizure activity  
    - Being administered anticonvulsant medication  
  - Obtain intravenous (IV) access |
| Assessment/examination | - Undertake comprehensive history and assessment of baby:  
  - Refer to Table 8. Assessment  
  - Refer to Table 9. Initial investigations  
  - Commence early discussions with neonatologist for paediatric neurology input through local retrieval services regarding assessment, initial management and potential for transfer to tertiary neonatal unit |
| Treat underlying causes | - Biochemical causes e.g. hypoglycaemia\(^{13,35}\)  
  - [refer to Queensland Clinical Guideline Newborn hypoglycaemia\(^{45}\)]  
  - Suspected bacterial infection according to local protocols or with empirical antibiotic therapy [refer to Queensland Clinical Guideline Early onset Group B Streptococcal disease for dosing regimens\(^{40}\)]  
    - Commence:  
      - Benzyl penicillin IV AND gentamicin IV OR  
      - Amoxicillin/ampicillin IV AND gentamicin IV AND  
    - Also commence Cefotaxime IV if bacterial meningitis is suspected  
  - Commence Acyclovir IV until CSF PCR for HSV is known to be negative  
  - Other underlying causes\(^35\) e.g. HIE—refer to Queensland Clinical Guideline Hypoxic-ischaemic encephalopathy\(^{24}\)  
  - In the absence of hypoglycaemia commence AED\(^{35}\)  
  - Treat other common biochemical derangements such as:  
    - Hypocalcaemia\(^8\)—with 10% calcium gluconate IV 2 mL/kg over 10 minutes and with cardiac monitoring\(^{36,46}\)  
    - Hypomagnesaemia\(^8\)—with 50% magnesium sulphate\(^36\) deep intramuscular injection 100 mg/kg\(^{39}\)  
  - If maternal substance use known or suspected—consider neonatal abstinence syndrome—refer to Queensland Clinical Guideline Perinatal substance use–neonatal and Queensland Clinical Guideline Perinatal substance use–maternal\(^{32,33}\) |
### 5.1.1 Continuing care

Table 12. Continuing care

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Comment/good practice point</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Medications</strong></td>
<td>• Refer to Section 6 Drug therapy</td>
</tr>
<tr>
<td><strong>EEG</strong></td>
<td>• Commence EEG monitoring if available, ideally with video recording</td>
</tr>
<tr>
<td></td>
<td>• Clinical observation alone may:</td>
</tr>
<tr>
<td></td>
<td>o Over detect apparent seizure activity that has no EEG correlate[^39]</td>
</tr>
<tr>
<td></td>
<td>o Under detect clinical seizures that are identified on EEG[^39]</td>
</tr>
<tr>
<td></td>
<td>• Majority of electrographic seizures do not have any overt clinical signs[^19]</td>
</tr>
<tr>
<td><strong>Model of care</strong></td>
<td>• Provide family centred care</td>
</tr>
<tr>
<td></td>
<td>• Establish early and ongoing communication with parents</td>
</tr>
<tr>
<td></td>
<td>o Repeat information as often as required</td>
</tr>
<tr>
<td></td>
<td>• Discuss management plan and prognosis with honesty and sensitivity</td>
</tr>
<tr>
<td></td>
<td>• Document discussions in medical record</td>
</tr>
<tr>
<td></td>
<td>• Involve social worker to support parents and family</td>
</tr>
<tr>
<td></td>
<td>o Long term sequelae from the underlying cause of the seizures may have profound impact on quality of life for the baby and family</td>
</tr>
<tr>
<td><strong>Parents</strong></td>
<td>• Discuss baby’s condition and option for care and treatment with parents</td>
</tr>
<tr>
<td></td>
<td>• Refer to 7.1 Discharge planning</td>
</tr>
<tr>
<td><strong>Referral</strong></td>
<td>• Consider:</td>
</tr>
<tr>
<td></td>
<td>o Early discussion with neonatologist regarding assessment, diagnosis and potential for transfer to higher level nursery</td>
</tr>
<tr>
<td></td>
<td>o Telehealth</td>
</tr>
<tr>
<td></td>
<td>• Refer to Queensland Clinical Guideline <em>Neonatal stabilisation for retrieval</em>[^47]</td>
</tr>
<tr>
<td><strong>Documentation</strong></td>
<td>• Document any episode of unusual or stereotypical movement and alterations in autonomic functioning Refer to Table 8. Assessment</td>
</tr>
<tr>
<td></td>
<td>• Video (if available) abnormal movements simultaneously with recording of cardiorespiratory monitoring</td>
</tr>
</tbody>
</table>
6 Drug therapy

While pharmacological options for treatment of neonatal seizures have increased there is limited evidence regarding the optimal pharmacological treatment strategy. Consider benefits and risks of available options including potential efficacy, potential toxicity and side effects and anticipated rapidity of response. Phenobarbital is recommended as the drug to be used but there is no general agreement on the preferred drug(s) for second line treatment.

Table 13. Principles

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Comment/good practice point</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Context</strong></td>
<td>Evidence based recommendations from randomised controlled trials (RCT) is lacking regarding the relative benefits versus the risk of harm from AEDs used to treat neonatal seizures. Experimental data shows commonly used AEDs may cause neurotoxicity and neuronal apoptosis. Anticonvulsant drugs may not stop electroencephalographic seizures even if they are effective in reducing or eliminating the clinical manifestations (electro-clinical dissociation). Hypothermia and the re-warming phase of HIE management may alter AED pharmokinetics. Refer to Queensland Clinical Guideline HIE.</td>
</tr>
<tr>
<td><strong>Expert recommendations</strong></td>
<td>Administer an adequate loading dose following drug administration recommendations. Treat both clinical and subclinical seizures as they have similar pathophysiology. Phenobarbital is the preferred first line medication. Refer to Table 14. Phenobarbital.</td>
</tr>
<tr>
<td><strong>Principles</strong></td>
<td>Treating the underlying cause of the seizures is critical to prevent clinical deterioration, further brain damage and poor long term neurodevelopmental outcomes. Commence treatment when: Clinically apparent seizure lasts more than three minutes. More than two briefer seizures occur. Electroencephalographic seizures are present. Administer AEDs: Intravenously to achieve rapid onset of action and predictable blood levels. To achieve serum levels in the therapeutic range. To maximum dosage before introducing another AED.</td>
</tr>
<tr>
<td><strong>Maintenance and duration of treatment</strong></td>
<td>Optimal duration of treatment with anticonvulsants is unknown. Consider discussion with neonatologist or paediatric neurologist before introducing second line AED. Duration of treatment considerations include: Baby’s neurological status. EEG. Underlying aetiology. Cease anticonvulsants when free of seizures for 72 hours and neurological examination is normal. Targeted maintenance treatment for genetic and metabolic disorders usually lifelong. Treatment usually continued if there is known progress to epilepsy (e.g. structural brain malformations and neonatal epilepsy syndromes).</td>
</tr>
</tbody>
</table>
### 6.1 Anti-epileptic drugs

#### 6.1.1 Phenobarbital

**Table 14. Phenobarbital**

<table>
<thead>
<tr>
<th>Phenobarbital*</th>
<th>Dose and administration</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>• First line treatment</td>
<td>• Controls seizures in 43–85 % of babies</td>
</tr>
<tr>
<td></td>
<td>• May be diluted to 10 mg/mL in 0.9 % sodium chloride&lt;sup&gt;58&lt;/sup&gt;</td>
<td>• A second line drug is often required</td>
</tr>
<tr>
<td></td>
<td>• May be diluted 1:10 with water for injections&lt;sup&gt;46,59&lt;/sup&gt;</td>
<td>o Phenobarbital may be discontinued when there is a therapeutic level of the second line drug</td>
</tr>
<tr>
<td><strong>Loading dose:</strong></td>
<td>20 mg/kg IV&lt;sup&gt;13&lt;/sup&gt; over 15–30 minutes</td>
<td>• Therapeutic range of phenobarbital is 15–40 micrograms/mL taken before fifth dose</td>
</tr>
<tr>
<td></td>
<td>o No faster than 1 mg/kg/minute&lt;sup&gt;59&lt;/sup&gt;</td>
<td>• Drug accumulation may occur during first two weeks of life</td>
</tr>
<tr>
<td></td>
<td>• For refractory seizures administer:</td>
<td>• If phenytoin or valproate also administered altered levels may occur</td>
</tr>
<tr>
<td></td>
<td>o Additional doses of 5–10 mg/kg IV up to a total of 40 mg/kg (including initial dose) OR</td>
<td>• May cause extravasation and phlebitis</td>
</tr>
<tr>
<td></td>
<td>o One additional dose of 20 mg/kg IV</td>
<td>• Serum half-life is 40–200 hours&lt;sup&gt;56&lt;/sup&gt; limits need to wean when short term therapy&lt;sup&gt;13&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>• <strong>Very low birth weight</strong> (VLBW; less than 1500 grams) preterm baby:</td>
<td>• Side effects include respiratory depression, depressed level of consciousness, hypotension and hypotonia&lt;sup&gt;13&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>o May require less than 15 mg/kg IV</td>
<td>• Pharmokinetics are affected by therapeutic hypothermia&lt;sup&gt;46&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

<sup>*Refer to an Australian pharmacopoeia for complete drug information</sup>
6.1.2 Phenytoin

Table 15. Phenytoin

<table>
<thead>
<tr>
<th>Phenytoin*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Dose and administration</strong></td>
</tr>
<tr>
<td>• Second line anticonvulsant for seizures refractory to phenobarbital(^{38})</td>
</tr>
<tr>
<td>• <strong>Loading dose</strong>: 15–20 mg/kg IV over 30–60 minutes(^{46,58,59})</td>
</tr>
<tr>
<td>• <strong>Maintenance</strong>: 5 mg/kg per day(^{58}) or 2 mg/kg every 8–12 hours(^{46})</td>
</tr>
<tr>
<td>• <strong>Administration (loading and maintenance)</strong></td>
</tr>
<tr>
<td>o Dilute to 5 mL with 0.9% sodium chloride and precede and follow injection with 0.9% sodium chloride flush to avoid contact with glucose solution(^{46})</td>
</tr>
<tr>
<td>o Administer directly into large peripheral or central vein through large bore catheter</td>
</tr>
<tr>
<td>o Do not exceed infusion rate of 1–3 mg/kg/minute(^{58})</td>
</tr>
<tr>
<td>o Do not administer by intramuscular route as may cause soft tissue necrosis at injection site and is poorly absorbed with drug crystallisation in muscle(^{58})</td>
</tr>
<tr>
<td>• <strong>Comment</strong></td>
</tr>
<tr>
<td>o Monitor cardiac rhythm and rate and blood pressure and respiratory function during and after administration (for at least 15–60 minutes)—May cause arrhythmias and severe hypotension(^{13,46,58})</td>
</tr>
<tr>
<td>o Observe for extravasation and necrosis</td>
</tr>
<tr>
<td>o Use with caution in babies with hyperbilirubinaemia(^{13})</td>
</tr>
<tr>
<td>o Measure trough level 48 hours after loading dose—therapeutic level: 6-15 micrograms/mL in first weeks and then 10–20 micrograms/mL</td>
</tr>
<tr>
<td>o Half-life is unpredictable(^{46})</td>
</tr>
<tr>
<td>o Dose related adverse events include nystagmus (level 15–25 mg/mL) and ataxia and mental statues changes (level greater than 30 mg/mL)(^{58})</td>
</tr>
</tbody>
</table>

\(^*\)Refer to an Australian pharmacopoeia for complete drug information

6.1.3 Midazolam

Table 16. Midazolam

<table>
<thead>
<tr>
<th>Midazolam*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Dose and administration</strong></td>
</tr>
<tr>
<td>• Second line anticonvulsant for seizures refractory to phenobarbital</td>
</tr>
<tr>
<td>• <strong>Loading dose</strong>: 0.15 mg/kg (150 micrograms/kg) IV over five minutes</td>
</tr>
<tr>
<td>• <strong>Maintenance IV infusion</strong>: 60–400 micrograms/kg/ hour (1–7 micrograms/minute)</td>
</tr>
<tr>
<td>• <strong>Administration (loading and maintenance)</strong></td>
</tr>
<tr>
<td>o Dilute in 0.9% sodium chloride or 5% glucose</td>
</tr>
<tr>
<td>o Do not administer by rapid infusion as may cause respiratory depression, severe hypotension and seizures(^{58})</td>
</tr>
<tr>
<td>• <strong>Comment</strong></td>
</tr>
<tr>
<td>o May cause myoclonic jerking(^{56})</td>
</tr>
<tr>
<td>o May cause respiratory depression and hypotension when used in conjunction with narcotics(^{56})</td>
</tr>
<tr>
<td>o Avoid extravasation(^{58})</td>
</tr>
<tr>
<td>o Seldom arrests EEG evidence of seizure activity if phenobarbital has not been successful(^{56})</td>
</tr>
</tbody>
</table>

\(^*\)Refer to an Australian pharmacopoeia for complete drug information
### 6.1.4 Levetiracetam

**Table 17. Levetiracetam**

<table>
<thead>
<tr>
<th>Levetiracetam*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Dose and administration</strong></td>
</tr>
</tbody>
</table>
| • Second line anticonvulsant for seizures refractory to phenobarbital
| • **Loading** dose not required but may be given if urgent seizure control required
| | o No loading dose—10 mg/kg IV twice per day increasing by 10 mg/kg/day over three days to 30 mg/kg IV twice per day
| | o If loading dose—40 mg/kg IV followed by 10 mg/kg IV once per day
| | • **Maintenance** dose may be given orally without regards to feeds
| | o 10 mg/kg/dose orally every daily or in two divided doses increasing by 10 mg/kg/day over three days to 30 mg/kg/day
| • Dilute to a concentration 5–15 mg/mL and infuse over 15 minutes
| | • Maintenance dose may be given orally without regards to feeds
| • Therapeutic levels monitoring generally not required but are approximately 10–40 micrograms/mL
| • Side effects include mild sedation, drowsiness and irritability
| • Taper doses when discontinuing as abrupt withdrawal increases risk of seizures
| • Data regarding adverse effects in neonates is limited to case reports and abstracts
| • Does not induce cell death in the developing brain (apoptosis)

*Refer to an Australian pharmacopoeia for complete drug information

### 6.1.5 Topiramate

**Table 18. Topiramate**

<table>
<thead>
<tr>
<th>Topiramate*^</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Dose and administration</strong></td>
</tr>
</tbody>
</table>
| • May be considered as second line anticonvulsant for seizures refractory to phenobarbital
| • If normothermia:
| | o **Dose**: 5 mg/kg orally once every 24 hours
| | If therapeutic hypothermia:
| | o **Loading dose**: 5 mg/kg orally on day 1
| | o **Maintenance**: 3 mg/kg orally once per day for duration of hypothermia
| • Broad-spectrum AED used to treat adults and children and increasingly 'off label' use for difficult to treat neonatal seizures
| • Does not exacerbate apoptosis after a severe hypoxic ischemic insult
| • May have anti-epileptogenic and neuroprotective effects
| • The gap between effective and neurotoxic doses (50 mg/kg) is greater for topiramate than other commonly used AEDs
| | o Short courses appear to have few neurotoxic effects
| • Is associated with cognitive and neuropsychiatric adverse events
| • Pharmacokinetic and safety data for long term use has not been established in neonatal population

*Refer to an Australian pharmacopoeia for complete drug information

^Topiramate is not on the Queensland Health (QH) List of Approved Medications (LAM)
6.1.6 Clonazepam

Table 19. Clonazepam

<table>
<thead>
<tr>
<th>Clonazepam*</th>
<th>Dose and administration</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>• Second line treatment for seizures $^{58}$</td>
<td>• Adverse effects include drowsiness, bronchial hypersecretion and salivation $^{46,58}$</td>
</tr>
<tr>
<td></td>
<td>• Dose: 100 micrograms/kg IV over five minutes once/day for 2 to 3 days $^{46}$</td>
<td>• Seldom arrests EEG evidence of seizure activity if phenobarbital has not been successful $^{58}$</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Sedative effect may mask cortical seizure activity that has not been suppressed</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Concurrent treatment with phenytoin reduces the half-life of clonazepam $^{46}$</td>
</tr>
</tbody>
</table>

*Refer to an Australian pharmacopoeia for complete drug information

6.1.7 Lidocaine (lignocaine)

Table 20. Lidocaine (lignocaine)

<table>
<thead>
<tr>
<th>Lidocaine (lignocaine)*</th>
<th>Dose and administration</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>• Used for severe recurrent or prolonged seizures not responding to first line treatment</td>
<td>• Dosing depends on gestation and the presence of hypothermia $^{46}$</td>
</tr>
<tr>
<td></td>
<td>• Loading dose for term normothermic babies: 2 mg/kg IV injection over 10 minutes followed immediately by maintenance infusion</td>
<td>• Preterm and hypothermic babies at risk of drug accumulation</td>
</tr>
<tr>
<td></td>
<td>• Maintenance IV infusion: 6 mg/kg/hour for 6 hours; then 4 mg/kg/hour for 12 hours; then 2 mg/kg/hour for 12 hours $^{13,46}$</td>
<td>• Do not use:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>o Concurrently with phenytoin because of cardiac effects or</td>
</tr>
<tr>
<td></td>
<td></td>
<td>o In babies with congenital heart disease $^{19}$</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Monitor ECG, blood pressure and heart rate</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Only use preservative free ampoules without adrenaline (epinephrine) $^{58}$</td>
</tr>
</tbody>
</table>

*Refer to an Australian pharmacopoeia for complete drug information
### 6.2 Pyridoxine (vitamin B6) deficiency

#### Table 21. Pyridoxine

<table>
<thead>
<tr>
<th>Pyridoxine (vitamin B6)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Diagnosis and treatment</strong></td>
<td></td>
</tr>
<tr>
<td>• Classic presentation is intractable seizures that appear within hours of birth and are resistant to conventional AEDs</td>
<td></td>
</tr>
<tr>
<td>o Baby responds rapidly to IV Pyridoxine</td>
<td></td>
</tr>
<tr>
<td>• May present with frequent multifocal and erratic or generalised myoclonic jerks</td>
<td></td>
</tr>
<tr>
<td>o May also present with tonic seizures, spasms, abnormal eye movements, grimacing or irritability</td>
<td></td>
</tr>
<tr>
<td>• Seizures may occur without ictal changes on the EEG</td>
<td></td>
</tr>
<tr>
<td>• Maternal history may report sensation of sustained hammering lasting 15–20 minutes by fetus inutero</td>
<td></td>
</tr>
<tr>
<td><strong>Dose and administration</strong></td>
<td></td>
</tr>
<tr>
<td>• Used for diagnosis and treatment of pyridoxine dependent seizures</td>
<td></td>
</tr>
<tr>
<td>o 50–100 mg IV injection over 20 minutes or IM</td>
<td></td>
</tr>
<tr>
<td>o If required may be repeated after 10 minutes up to a total maximum dose of 500 mg</td>
<td></td>
</tr>
<tr>
<td>• If responsive then administer 50–100 mg orally once per day</td>
<td></td>
</tr>
<tr>
<td><strong>Comment</strong></td>
<td></td>
</tr>
<tr>
<td>• Vitamin B6 is a required enzyme in the biosynthesis of dopamine and serotonin</td>
<td></td>
</tr>
<tr>
<td>• Used to treat inborn error of metabolism due to antiquitin deficiency (α-amino adipic semialdehyde [α-AASA] dehydrogenase deficiency)</td>
<td></td>
</tr>
<tr>
<td>• Consider pyridoxine dependency in any baby with severe seizures even if there is a clear cause (e.g. birth asphyxia)</td>
<td></td>
</tr>
<tr>
<td>• Seizures are usually multifocal and clonic at onset and progress rapidly to status epilepticus</td>
<td></td>
</tr>
<tr>
<td>• Observe for bradycardia, apnoea, hypotension and hypotonia</td>
<td></td>
</tr>
<tr>
<td>o Monitor cardio-respiratory function</td>
<td></td>
</tr>
<tr>
<td>o Ventilator support may be necessary</td>
<td></td>
</tr>
<tr>
<td>• Best administered while EEG monitoring but absence of EEG should not delay administration</td>
<td></td>
</tr>
<tr>
<td>• A pyridoxine level of less than 20 nanomoles/L is indicative of a deficiency</td>
<td></td>
</tr>
</tbody>
</table>

*Refer to an Australian pharmacopoeia for complete drug information*
7 Ongoing care

7.1 Discharge planning

Document discussions with parents, including the management plan (including emergency seizure management at home), prognosis, and parental decisions to enable consistency of information. Provide the parents with appropriate discharge information and documentation including:

- A seizure emergency management plan
- A copy of the discharge summary including the type of seizures and medications
- Contact details of available support services available in the local area or online
- Copies of referrals to other services
- Follow up appointments if available

7.2 Prognosis

Neonatal seizures can cause both acute effects and long term sequelae. Acute and long term adverse effects result from energy failure, excitotoxicity, neuronal death, apoptosis and status epilepticus. These all contribute to cognitive, motor and behavioural problems.64

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Prognosis</strong></td>
<td>• Determined by aetiology222</td>
</tr>
<tr>
<td></td>
<td>• Strongest predictors of outcome–underlying cause and background EEG activity20,22,65</td>
</tr>
<tr>
<td></td>
<td>• Tends to be worse for preterm babies11 as often associated with underlying brain injury20,65</td>
</tr>
<tr>
<td></td>
<td>• If EEG background is normal:</td>
</tr>
<tr>
<td></td>
<td>o Prognosis is excellent for resolution of seizures</td>
</tr>
<tr>
<td></td>
<td>o Normal development is likely22</td>
</tr>
<tr>
<td><strong>Morbidity and mortality</strong></td>
<td>• Risk of long term morbidity and neonatal mortality22</td>
</tr>
<tr>
<td></td>
<td>• Complications include22:</td>
</tr>
<tr>
<td></td>
<td>o Cerebral palsy</td>
</tr>
<tr>
<td></td>
<td>o Cerebral atrophy</td>
</tr>
<tr>
<td></td>
<td>o Hydrocephalus ex-vacuo</td>
</tr>
<tr>
<td></td>
<td>o Microcephaly</td>
</tr>
<tr>
<td></td>
<td>o Epilepsy</td>
</tr>
<tr>
<td></td>
<td>o Spasticity</td>
</tr>
<tr>
<td></td>
<td>o Feeding difficulties</td>
</tr>
</tbody>
</table>
### 7.3 Outcomes

Babies who experience neonatal seizures are more likely to have neurodevelopmental disability and are at greater risk of developing epilepsy\(^2\).  

#### Table 23. Outcomes

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>• Relatively poor long term outcomes associated with diffuse brain injury including:</td>
</tr>
<tr>
<td></td>
<td>o Generalised myoclonic seizures</td>
</tr>
<tr>
<td></td>
<td>o Generalised tonic seizures</td>
</tr>
<tr>
<td></td>
<td>o Motor automatisms (subtle seizures)(^2)</td>
</tr>
<tr>
<td></td>
<td>• Other factors associated with poor outcome include:</td>
</tr>
<tr>
<td></td>
<td>o Severe abnormalities on neurologic examination(^2)</td>
</tr>
<tr>
<td></td>
<td>o Prematurity especially those with most serious life threatening illnesses</td>
</tr>
<tr>
<td></td>
<td>o Early onset (within 48 hours of birth)</td>
</tr>
<tr>
<td></td>
<td>o Repeated seizures of greater than or equal to one hour in duration</td>
</tr>
<tr>
<td></td>
<td>o Recurrent seizures of greater than 48 hours(^2)</td>
</tr>
<tr>
<td></td>
<td>• Cerebral dysgenesis</td>
</tr>
<tr>
<td></td>
<td>• CNS infection</td>
</tr>
<tr>
<td></td>
<td>• Severe IVH</td>
</tr>
<tr>
<td></td>
<td>• Severely abnormal EEG inter-ictal activity(^65) (isoelectric pattern, paroxysmal, burst-suppression and low voltage background)(^20)</td>
</tr>
<tr>
<td></td>
<td>• More than one AED to control seizures</td>
</tr>
<tr>
<td></td>
<td>• Less strongly associated:</td>
</tr>
<tr>
<td></td>
<td>o Severely abnormal neurological examination</td>
</tr>
<tr>
<td></td>
<td>o Severely abnormal neuroimaging</td>
</tr>
<tr>
<td></td>
<td>o Early onset seizures (within 24 hours of birth related to HIE in term babies)</td>
</tr>
<tr>
<td></td>
<td>o Severity of seizures</td>
</tr>
<tr>
<td></td>
<td>o Presence of status epilepticus(^20,65)</td>
</tr>
<tr>
<td></td>
<td>• Associated with favourable outcome</td>
</tr>
<tr>
<td></td>
<td>• Normal neurological examination(^20)</td>
</tr>
<tr>
<td></td>
<td>• Focal brain injury and relatively sparing of greater regions of brain tend to have more favourable outcomes(^2)</td>
</tr>
<tr>
<td></td>
<td>• Focal clonic seizures:</td>
</tr>
<tr>
<td></td>
<td>o Including benign familial neonatal seizures(^2,20)</td>
</tr>
<tr>
<td></td>
<td>o Benign idiopathic neonatal seizures</td>
</tr>
<tr>
<td></td>
<td>o Transient metabolic disturbance (e.g. hypocalcaemia)(^20,65)</td>
</tr>
<tr>
<td></td>
<td>o Focal lesions (brain haemorrhage or stroke) on MR(^20)</td>
</tr>
<tr>
<td></td>
<td>o Lesion confined to relatively circumscribed areas of the brain(^2)</td>
</tr>
<tr>
<td></td>
<td>• Brief or rarely reoccurring seizures</td>
</tr>
<tr>
<td></td>
<td>• Clinical seizures with no EEG correlate</td>
</tr>
<tr>
<td></td>
<td>• Normal inter-ictal EEG</td>
</tr>
<tr>
<td></td>
<td>• Neonatal sleep myoclonus</td>
</tr>
<tr>
<td></td>
<td>• Less strongly associated:</td>
</tr>
<tr>
<td></td>
<td>o Normal/mild abnormality on neuroimaging</td>
</tr>
<tr>
<td></td>
<td>o Late onset (i.e. greater than five days of age; related to benign neonatal seizures)</td>
</tr>
<tr>
<td></td>
<td>o Focal clonic seizures (likely related to focal structural lesion in the brain)(^20)</td>
</tr>
</tbody>
</table>
7.4 Follow up

Table 24. Follow up

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Comment/good practice point</th>
</tr>
</thead>
</table>
| Context         | • Preterm babies are at greater risk of poor neurodevelopmental outcomes⁴²  
• Follow up by multidisciplinary team to assess developmental outcomes¹⁰  
• Depends on cause of seizures and response to treatment  

Follow up care  
• Facilitate follow up with verbal and written communication and assistance with appointments as required:  
  o General practitioner and child health nurse  
  o Paediatrician in local area  
  o Paediatric neurologist or neonatologist according to local arrangements if baby discharged home on AEDs  
    • Telehealth may be used where available  
  o Multi-disciplinary team to identify any motor and cognitive deficits and timely neuro-developmental early intervention⁶⁶,⁶⁷ using simple tools such as the General Movements Assessment (GMA), parent screening and use of Ages and Stages questionnaire⁶⁸  
    • Early intervention when the brain is most plastic minimises developmental disabilities⁶⁶  
    • Abnormal fidgety GMA at three months of age is predictive for neurodevelopmental delay such as cerebral palsy⁶⁶,⁶⁹  
    • GMA requires 15 minutes of observation of the baby by a trained observer in the fidgety movements stage (i.e. three months corrected age) and has been validated in term (with HIE) and preterm babies⁶⁹ as a predictor of cerebral palsy.⁶⁷  
    • Review by appropriately trained clinicians of GMA video recording is required.  
  • Provide parents with a written seizure emergency management plan and a copy of the discharge plan including the types of seizures the baby had and any medication used to treat
References

28. RANZCOG. Care of women with confirmed Zika virus infection during pregnancy in Australia. 2016.


34. Holmes G. Neonatal seizures. In Clinical Key [Internet]. 2013 May 8 [Cited 1 September 2016].


58. Micromedex Solutions. Paediatrics and Neofax [Internet]. 2016
Appendix A Abnormal movements

Abnormal movements in newborn baby

Seizure Activity

Electrographical

Focal
Seizure activity involves one area of brain affecting one side of body

Multifocal
Seizure activity involves more than one area of brain affecting several body parts

Generalised
Seizure activity involves both hemispheres of brain

Clinical
• Clonic–recurrent muscle contraction
• Tonic–sustained muscle contraction
• Myoclonic–brief active muscle contraction
• Subtle–automatisms
  o Autonomic phenomena
  o Ocular-orbital phenomena
  o Orolingual phenomena
  o Hypomotor

Non-seizure activity

Jitteriness
• Excessive startles
• Benign neonatal sleep clonus
• Tremors
• Clonus

Jitteriness versus seizures

<table>
<thead>
<tr>
<th>Clinical features</th>
<th>Jitteriness</th>
<th>Seizures</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abnormal gaze/eye movement</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>Predominant movement</td>
<td>Tremor, rapid, oscillatory</td>
<td>Clonic, jerking, tonic</td>
</tr>
<tr>
<td>Movements cease with passive flexion</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Stimulus provoked movement</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Conscious state/autonomic change</td>
<td>Awake or asleep</td>
<td>Altered</td>
</tr>
</tbody>
</table>

Orolingual
• Mouthing/Chewing
• Tongue movements
• Crying
• Yawning
• Noises or vocalisation
• Dry retching

Ocular-orbital
• Opening
• Flickering
• Deviation
• Nystagmus

Autonomic
• Colour change
• Sigh/grasp/breathing change
• Oxygen saturation
• Apnoea
• Heart rate change (by > 10)
• Blood pressure increase or decrease

Hypomotor
• Motionless/mark reduction in activity
• Staring

Queensland Clinical Guidelines F17.23-3-V1-R22 Neonatal seizures: Abnormal movements
Acknowledgements

Queensland Clinical Guidelines gratefully acknowledge the contribution of Queensland clinicians and other stakeholders who participated throughout the guideline development process particularly:

**Working Party Clinical Lead**
Professor Paul Colditz

**QCG Program Officer**
Ms Stephanie Sutherns

**Working Party Members**
Mrs Seija Argyros, Neonatal Nurse Practitioner, Royal Brisbane & Women's Hospital
Miss Angela Backen, Registered Nurse, Royal Brisbane & Women's Hospital
Mrs Maxine Ballinger, Clinical Nurse Consultant, Rockhampton Hospital
Mrs Josephine Bell, Registered Midwife, Stanthorpe Hospital
Mrs Rachael Berghuis, Clinical Nurse, Gold Coast University Hospital
Mrs Deb Byrt, Clinical Nurse Midwife, The Sunshine Coast Private Hospital
Ms Tanya Capper, Acting Head of Program (Midwifery), Central Queensland University
Ms Liz Chappell, Neonatal Nurse Educator, Gold Coast University Hospital
Dr Mark Davies, Neonatologist, Royal Brisbane & Women's Hospital
Dr Hazel Dobinson, Rural General Practitioner, Children's Health Queensland
Dr John Gavranich, Director of Paediatrics, Ipswich Hospital
Mrs Corne' Gouws, Clinical Nurse, Gold Coast University Hospital
Mr John Graham, Midwife, Caboolture Hospital
Ms Tina Gray, Clinical Nurse, Hervey Bay Hospital
Mrs Danielle Groves, Registered Nurse Midwife, Hervey Bay Hospital
Mrs Jodie Hole, Registered Nurse Midwife, Sunshine Coast Private Hospital
Ms Karen Hose, Neonatal Nurse Practitioner, Royal Brisbane & Women's Hospital
Dr Arif Huq, Paediatrician, Logan Hospital
Dr Peter Kopp, Paediatric Registrar, Gold Coast University Hospital
Ms Cathy Krause, Clinical Nurse and Midwife, St Vincent's Hospital Toowoomba
Mrs Nicole Lindenberg, Registered Nurse Midwife, St Vincent's Hospital, Toowoomba
Dr Stephen Malone, Paediatric Neurologist, Lady Cilento Children's Hospital, Brisbane
Mrs Hayley McGillivray, Clinical Nurse, Hervey Bay Hospital
Dr Parvin Niknafs, Midwife, The Wesley Hospital, Brisbane
Ms Marian Rigney, Associate Nurse Unit Manager, Logan-Bayside Network
Mrs Erika Rossouw, Clinical Nurse, Gold Coast University Hospital
Dr Peter Schmidt, Director of Neonatology, Gold Coast University Hospital
Ms Alecia Staines, Consumer Representative, Maternity Consumer Network
Dr Lizelle Weber, Acting Director of Neonatology, Nambour Hospital
Dr Karen Whitfield, Senior Pharmacist, Royal Brisbane & Women's Hospital

**Queensland Clinical Guidelines Team**
Associate Professor Rebecca Kimble, Director
Ms Jacinta Lee, Manager
Ms Stephanie Sutherns, Clinical Nurse Consultant
Ms Cara Cox, Clinical Nurse Consultant
Dr Brent Knack, Program Officer
Steering Committee

**Funding**
This clinical guideline was funded by Healthcare Improvement Unit, Queensland Health